Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

336 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study.
García-Suárez J, de la Cruz J, Cedillo Á, Llamas P, Duarte R, Jiménez-Yuste V, Hernández-Rivas JÁ, Gil-Manso R, Kwon M, Sánchez-Godoy P, Martínez-Barranco P, Colás-Lahuerta B, Herrera P, Benito-Parra L, Alegre A, Velasco A, Matilla A, Aláez-Usón MC, Martos-Martínez R, Martínez-Chamorro C, Susana-Quiroz K, Del Campo JF, de la Fuente A, Herráez R, Pascual A, Gómez E, Pérez-Oteyza J, Ruiz E, Alonso A, González-Medina J, Martín-Buitrago LN, Canales M, González-Gascón I, Vicente-Ayuso MC, Valenciano S, Roa MG, Monteliu PE, López-Jiménez J, Escobar CE, Ortiz-Martín J, Diez-Martin JL, Martinez-Lopez J; Asociación Madrileña de Hematología y Hemoterapia (AMHH). García-Suárez J, et al. Among authors: canales m. J Hematol Oncol. 2020 Oct 8;13(1):133. doi: 10.1186/s13045-020-00970-7. J Hematol Oncol. 2020. PMID: 33032660 Free PMC article.
Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide.
Martínez-López J, Rivero A, Rapado I, Montalbán C, Paz-Carreira J, Canales M, Martínez R, Sánchez-Godoy P, Fernández de Sevilla A, Peñalver FJ, Gonzalez M, Prieto E, Salar A, Burgaleta C, Queizán JA, Peñarrubia MJ, Monteagudo MD, Cabrera C, De la Serna J, Tomás JF. Martínez-López J, et al. Among authors: canales m. Leuk Lymphoma. 2009 Aug;50(8):1283-9. doi: 10.1080/10428190903040006. Leuk Lymphoma. 2009. PMID: 19557622
Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series.
Guisado-Vasco P, Arranz-Saez R, Canales M, Cánovas A, Garcia-Laraña J, García-Sanz R, Lopez A, López JL, Llanos M, Moraleda JM, Rodriguez J, Rayón C, Sabin P, Salar A, Marín-Niebla A, Morente M, Sánchez-Godoy P, Tomás JF, Muriel A, Abraira V, Piris MA, Garcia JF, Montalban C; Spanish Hodgkin Lymphoma Study Group. Guisado-Vasco P, et al. Among authors: canales m. Leuk Lymphoma. 2012 May;53(5):812-9. doi: 10.3109/10428194.2011.635861. Epub 2012 Jan 31. Leuk Lymphoma. 2012. PMID: 22185637
Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03).
Tomás JF, Montalbán C, De Sevilla AF, Martínez-López J, Díaz N, Canales M, Martínez R, Sánchez-Godoy P, Caballero MD, Peñalver J, Prieto E, Salar A, Burgaleta C, Queizán JA, Bajo R, De Oña R, De La Serna J. Tomás JF, et al. Among authors: canales m. Leuk Lymphoma. 2011 Mar;52(3):409-16. doi: 10.3109/10428194.2010.543717. Epub 2011 Jan 28. Leuk Lymphoma. 2011. PMID: 21275633 Clinical Trial.
MicroRNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma.
Sánchez-Espiridión B, Martín-Moreno AM, Montalbán C, Figueroa V, Vega F, Younes A, Medeiros LJ, Alvés FJ, Canales M, Estévez M, Menarguez J, Sabín P, Ruiz-Marcellán MC, Lopez A, Sánchez-Godoy P, Burgos F, Santonja C, López JL, Piris MA, Garcia JF. Sánchez-Espiridión B, et al. Among authors: canales m. Br J Haematol. 2013 Aug;162(3):336-47. doi: 10.1111/bjh.12390. Epub 2013 Jun 1. Br J Haematol. 2013. PMID: 23725219 Free PMC article.
Lessons learned for successful treatment of AML in the second wave of COVID-19 outbreak.
Ramírez-López A, Lázaro Del Campo P, Humala K, De la Cruz Benito B, Sánchez-Vadillo I, López de la Guía A, de Paz Arias R, Jiménez-Yuste V, Canales M. Ramírez-López A, et al. Among authors: canales m. Leuk Lymphoma. 2021 Aug;62(8):2034-2036. doi: 10.1080/10428194.2021.1886291. Epub 2021 Feb 28. Leuk Lymphoma. 2021. PMID: 33645389 No abstract available.
A new prognostic model identifies patients aged 80 years and older with diffuse large B-cell lymphoma who may benefit from curative treatment: A multicenter, retrospective analysis by the Spanish GELTAMO group.
Pardal E, Díez Baeza E, Salas Q, García T, Sancho JM, Monzón E, Moraleda JM, Córdoba R, de la Cruz F, Queizán JA, Rodríguez MJ, Navarro B, Hernández JA, Díez R, Vahi M, Viguria MC, Canales M, Peñarrubia MJ, González-López TJ, Montes-Moreno S, González-Barca E, Caballero D, Martín A; GELTAMO Spanish Collaborative Group. Pardal E, et al. Among authors: canales m. Am J Hematol. 2018 Jul;93(7):867-873. doi: 10.1002/ajh.25107. Epub 2018 May 6. Am J Hematol. 2018. PMID: 29658143 Free article.
336 results